EU Drug Regulator Endorses Six New Medicines for Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- New Drug Approvals: The European Medicines Agency endorsed six new medicines and 11 label expansions this week, which is expected to significantly benefit drugmakers including Eli Lilly (LLY), Incyte (INCY), and CSL Limited (CSLLY).
- Eli Lilly's Progress: Eli Lilly announced that its cancer drug Jaypirca received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for chronic lymphocytic leukemia treatment, with final approval anticipated in the next one to two months, further solidifying its market position in blood cancer therapies.
- Incyte Label Expansion: Incyte's JAK inhibitor Opzelura (ruxolitinib) cream received a positive opinion from the EMA, and if finalized, it will serve as a second-line treatment for moderate atopic dermatitis, expanding its market application.
- CSL Vaccine Approval: CSL Limited's subsidiary Seqirus Netherlands received EU backing for its Aujemflu vaccine to prevent influenza in individuals aged 50 and above, enhancing its competitive edge in the vaccine market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1127.690
Low
950.00
Averages
1192
High
1500
Current: 1127.690
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches Memory Radio Station in Geneva
- Memory Radio Station Launch: Eli Lilly has launched The Memory Radio Station at the European Academy of Neurology Congress in Geneva, aiming to raise public awareness about early symptoms of Alzheimer's disease and the importance of recognizing memory changes.
- Multi-Country Tour: The initiative will travel to multiple European countries including Austria, Germany, Italy, and Belgium, engaging the public to share personal memories and enhance awareness of brain health.
- Generative AI Utilization: Visitors can participate in the Synthetic Memories project at The Memory Radio Station, using generative AI to visualize personal memories, helping individuals reconnect with moments that shape their identity.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections rising to 17.5 million by 2050, highlighting the urgent need for increased public awareness as early symptoms are often overlooked.
See More
EU Drug Regulator Endorses Six New Medicines for Approval
- New Drug Approvals: The European Medicines Agency endorsed six new medicines and 11 label expansions this week, which is expected to significantly benefit drugmakers including Eli Lilly (LLY), Incyte (INCY), and CSL Limited (CSLLY).
- Eli Lilly's Progress: Eli Lilly announced that its cancer drug Jaypirca received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for chronic lymphocytic leukemia treatment, with final approval anticipated in the next one to two months, further solidifying its market position in blood cancer therapies.
- Incyte Label Expansion: Incyte's JAK inhibitor Opzelura (ruxolitinib) cream received a positive opinion from the EMA, and if finalized, it will serve as a second-line treatment for moderate atopic dermatitis, expanding its market application.
- CSL Vaccine Approval: CSL Limited's subsidiary Seqirus Netherlands received EU backing for its Aujemflu vaccine to prevent influenza in individuals aged 50 and above, enhancing its competitive edge in the vaccine market.
See More
New Medicare Program Expands Access to Weight Loss Drugs for Millions
- Medicare Program Launch: The new Medicare GLP-1 Bridge program will provide eligible Medicare Part D beneficiaries access to specific GLP-1 drugs from July 1, 2026, to December 31, 2027, with a predictable $50 copayment, significantly reducing patient financial burdens.
- Drug Coverage Scope: The program covers Eli Lilly's Foundayo and Zepbound KwikPen, as well as Novo Nordisk's Wegovy (both injection and tablets), but only for weight loss purposes, with an estimated 3 million people expected to qualify for participation.
- Market Potential Surge: Morgan Stanley Research anticipates that the expansion of Medicare access and the launch of oral GLP-1 therapies will elevate the global GLP-1 drug market to $190 billion by 2035, an increase of $40 billion from previous estimates, indicating substantial growth potential.
- Treatment Adoption Increase: By 2035, nearly 30% of obese or diabetic individuals in the U.S. are projected to receive GLP-1 therapy, with the global rate rising to 10%, significantly boosting drug demand and company revenues.
See More
Eli Lilly's Jaypirca Nears European Approval for CLL Treatment
- Regulatory Positive Opinion: Eli Lilly's Jaypirca (pirtobrutinib) has received a positive opinion from the CHMP, supporting its use in adults with chronic lymphocytic leukemia (CLL) across all lines of therapy, marking a significant step towards expanding market access for its next-generation BTK inhibitor.
- Clinical Trial Support: This recommendation is backed by results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, which demonstrated strong efficacy and tolerability of Jaypirca in both treatment-naïve patients and those previously treated with BTK inhibitors, enhancing its competitive position in the market.
- Therapeutic Innovation: BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in newly diagnosed CLL, while BRUIN CLL-314 is the first trial to directly compare non-covalent and covalent BTK inhibitors in this setting, highlighting Jaypirca's significance in treatment sequencing.
- Optimistic Market Outlook: With the CHMP's positive opinion now sent to the European Commission, a final decision is expected within the next one to two months, and if approved, it will significantly enhance Eli Lilly's market share in CLL treatment, with the stock currently trading at $1,194.76, up 5.86%.
See More
Challenges Ahead for GLP-1 Weight Loss Drugs
- Employer Coverage Concerns: A Mercer study indicates that 6% of large employers dropped GLP-1 medication coverage in 2026, with more cuts anticipated for 2027, reflecting ongoing worries about the rising costs of these drugs.
- Impact of Rising Costs: According to an NFP survey, 51% of employers cite GLP-1s as the primary driver of increasing prescription drug costs, highlighting a disconnect between strong employee demand for weight-loss medications and employers' reluctance to absorb high expenses, leading to tighter coverage policies.
- Effectiveness vs. Cost Dilemma: Although the oral GLP-1 medications are priced similarly to injectables, clinical trials suggest they are less effective for weight loss, which may lead some employers to exclude them from their drug coverage lists, further limiting employee options.
- Future Market Competition Expectations: Currently, only two major pharmaceutical companies produce GLP-1 drugs, restricting market competition; however, the anticipated introduction of new drugs within the next year is expected to increase competition and potentially drive prices down, although consumers will continue to face high costs in the short term.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
Eli Lilly Launches Memory Radio Station in Geneva
- Memory Radio Station Launch: Eli Lilly has launched The Memory Radio Station at the European Academy of Neurology Congress in Geneva, aiming to raise public awareness about early symptoms of Alzheimer's disease and the importance of recognizing memory changes.
- Multi-Country Tour: The initiative will travel to multiple European countries including Austria, Germany, Italy, and Belgium, engaging the public to share personal memories and enhance awareness of brain health.
- Generative AI Utilization: Visitors can participate in the Synthetic Memories project at The Memory Radio Station, using generative AI to visualize personal memories, helping individuals reconnect with moments that shape their identity.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections rising to 17.5 million by 2050, highlighting the urgent need for increased public awareness as early symptoms are often overlooked.
See More
EU Drug Regulator Endorses Six New Medicines for Approval
- New Drug Approvals: The European Medicines Agency endorsed six new medicines and 11 label expansions this week, which is expected to significantly benefit drugmakers including Eli Lilly (LLY), Incyte (INCY), and CSL Limited (CSLLY).
- Eli Lilly's Progress: Eli Lilly announced that its cancer drug Jaypirca received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for chronic lymphocytic leukemia treatment, with final approval anticipated in the next one to two months, further solidifying its market position in blood cancer therapies.
- Incyte Label Expansion: Incyte's JAK inhibitor Opzelura (ruxolitinib) cream received a positive opinion from the EMA, and if finalized, it will serve as a second-line treatment for moderate atopic dermatitis, expanding its market application.
- CSL Vaccine Approval: CSL Limited's subsidiary Seqirus Netherlands received EU backing for its Aujemflu vaccine to prevent influenza in individuals aged 50 and above, enhancing its competitive edge in the vaccine market.
See More
New Medicare Program Expands Access to Weight Loss Drugs for Millions
- Medicare Program Launch: The new Medicare GLP-1 Bridge program will provide eligible Medicare Part D beneficiaries access to specific GLP-1 drugs from July 1, 2026, to December 31, 2027, with a predictable $50 copayment, significantly reducing patient financial burdens.
- Drug Coverage Scope: The program covers Eli Lilly's Foundayo and Zepbound KwikPen, as well as Novo Nordisk's Wegovy (both injection and tablets), but only for weight loss purposes, with an estimated 3 million people expected to qualify for participation.
- Market Potential Surge: Morgan Stanley Research anticipates that the expansion of Medicare access and the launch of oral GLP-1 therapies will elevate the global GLP-1 drug market to $190 billion by 2035, an increase of $40 billion from previous estimates, indicating substantial growth potential.
- Treatment Adoption Increase: By 2035, nearly 30% of obese or diabetic individuals in the U.S. are projected to receive GLP-1 therapy, with the global rate rising to 10%, significantly boosting drug demand and company revenues.
See More
Eli Lilly's Jaypirca Nears European Approval for CLL Treatment
- Regulatory Positive Opinion: Eli Lilly's Jaypirca (pirtobrutinib) has received a positive opinion from the CHMP, supporting its use in adults with chronic lymphocytic leukemia (CLL) across all lines of therapy, marking a significant step towards expanding market access for its next-generation BTK inhibitor.
- Clinical Trial Support: This recommendation is backed by results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, which demonstrated strong efficacy and tolerability of Jaypirca in both treatment-naïve patients and those previously treated with BTK inhibitors, enhancing its competitive position in the market.
- Therapeutic Innovation: BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in newly diagnosed CLL, while BRUIN CLL-314 is the first trial to directly compare non-covalent and covalent BTK inhibitors in this setting, highlighting Jaypirca's significance in treatment sequencing.
- Optimistic Market Outlook: With the CHMP's positive opinion now sent to the European Commission, a final decision is expected within the next one to two months, and if approved, it will significantly enhance Eli Lilly's market share in CLL treatment, with the stock currently trading at $1,194.76, up 5.86%.
See More
Challenges Ahead for GLP-1 Weight Loss Drugs
- Employer Coverage Concerns: A Mercer study indicates that 6% of large employers dropped GLP-1 medication coverage in 2026, with more cuts anticipated for 2027, reflecting ongoing worries about the rising costs of these drugs.
- Impact of Rising Costs: According to an NFP survey, 51% of employers cite GLP-1s as the primary driver of increasing prescription drug costs, highlighting a disconnect between strong employee demand for weight-loss medications and employers' reluctance to absorb high expenses, leading to tighter coverage policies.
- Effectiveness vs. Cost Dilemma: Although the oral GLP-1 medications are priced similarly to injectables, clinical trials suggest they are less effective for weight loss, which may lead some employers to exclude them from their drug coverage lists, further limiting employee options.
- Future Market Competition Expectations: Currently, only two major pharmaceutical companies produce GLP-1 drugs, restricting market competition; however, the anticipated introduction of new drugs within the next year is expected to increase competition and potentially drive prices down, although consumers will continue to face high costs in the short term.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
